Oculis (OCS) Set to Announce Earnings on Tuesday

Oculis (NASDAQ:OCS) is projected to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $0.25 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 12:30 PM ET.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The firm had revenue of $0.38 million during the quarter. On average, analysts expect Oculis to post ($2.01) EPS for the current fiscal year and ($2.05) EPS for the next fiscal year.

Oculis Stock Performance

Oculis stock traded up $0.10 during midday trading on Tuesday, hitting $8.00. 3,541 shares of the company’s stock were exchanged, compared to its average volume of 423,542. The stock has a market cap of $463.72 million, a price-to-earnings ratio of -4.58 and a beta of 0.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35. The firm’s 50 day simple moving average is $10.16 and its 200 day simple moving average is $19.06. Oculis has a 12-month low of $7.11 and a 12-month high of $34.47.

Analyst Upgrades and Downgrades

A number of research firms recently commented on OCS. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price target on shares of Oculis in a report on Wednesday, October 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Thursday, October 15th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oculis presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.44.

Oculis Company Profile

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.